服務(wù)熱線
13817140470
歡迎訪問(wèn)上海勁馬實(shí)驗(yàn)設(shè)備有限公司網(wǎng)站
13817140470時(shí)間:2021/8/6 瀏覽次數(shù):806
【文獻(xiàn)標(biāo)題】The participation of fibroblast growth factor 23 (FGF23)in the progression of osteoporosis via JAK/STAT pathway
【作者】Lijun Xu, Lixia Zhang,Huijuan Zhang,et.al
【作者單位】鄭州大學(xué)第一附屬醫(yī)院(The First Affiliated Hospital of Zhengzhou University)
【文獻(xiàn)中引用產(chǎn)品】
大鼠抗酒石酸酸性磷酸酶(TRAP)ELISA試劑盒
【關(guān)鍵詞】Osteoporosis; FGF23; JAK/STAT pathway; bone metabolism; cartilage metabolism
【DOI】10.1002/jcb.26332
【影響因子(IF)】2.9
【出版期刊】《Journal of Cellular Biochemistry》
【產(chǎn)品原文引用】
Measurement of serum FGF23, osteocalcin, ALP, BALP, TRAP and CTX-I
Serum FGF23 levels were measured by an enzyme linked immunosorbent assay (ELISA) using an FGF23 kit (Kainos Laboratories, Tokyo, Japan). Serum osteocalcin content was determined by ELISA using an Osteocalcin EIA kit (Xinyubio-Technology, China). ALP activity was determined by ELISA using an ALP activity kit (Nanjing Jiancheng Biotech, China). BALP was measured by an electrochemilumi-nescence immunoassay (ECL) using the Access Ostase kit (Beckman Coulter Inc, USA). TRAP activity was determined by ELISA using the Acid-Phosphatase Kit (Shanghai Jinma Biological Technology, China). CTX-I was also measured by ECL using the Elecsys-CrossLaps/serum kit (Roche, USA).
完整版PDF文獻(xiàn)請(qǐng)咨詢?cè)诰€客服或dian話聯(lián)系我司業(yè)務(wù)員!
更多公司福利請(qǐng)關(guān)注“上海勁馬"微信公眾號(hào)!
上海勁馬實(shí)驗(yàn)設(shè)備有限公司(huihuangzp.cn)主營(yíng):ELISA檢測(cè)試劑盒;免疫組化試劑盒,胎牛血清;酶聯(lián)免疫試劑盒,進(jìn)口抗體,生物試劑
地址:上海市松江區(qū)漕河涇研展路455號(hào)B座
版權(quán)所有 © 2024 上海勁馬實(shí)驗(yàn)設(shè)備有限公司 備案號(hào):滬ICP備15015681號(hào) 管理登陸 技術(shù)支持:環(huán)保在線 sitemap.xml